Acquisition of Patent for Oral Irinotecan Formulation with Conversation Constraints

[Asia Economy Reporter Minwoo Lee] Daehwa Pharmaceutical announced on the 9th that it has obtained a patent for an "oral pharmaceutical composition containing irinotecan or pharmaceutically acceptable salts thereof." This technology allows irinotecan to be formulated into capsules, securing a pipeline for the development of oral anticancer drugs following Liporaxel solution in the future.